KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-Current Deffered Revenue: 2018-2024

Historic Non-Current Deffered Revenue for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $27.3 million.

  • Adaptive Biotechnologies' Non-Current Deffered Revenue fell 96.32% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 96.32%. This contributed to the annual value of $27.3 million for FY2024, which is 39.15% down from last year.
  • Per Adaptive Biotechnologies' latest filing, its Non-Current Deffered Revenue stood at $27.3 million for FY2024, which was down 39.15% from $44.8 million recorded in FY2023.
  • In the past 5 years, Adaptive Biotechnologies' Non-Current Deffered Revenue registered a high of $163.6 million during FY2020, and its lowest value of $27.3 million during FY2024.
  • For the 3-year period, Adaptive Biotechnologies' Non-Current Deffered Revenue averaged around $43.5 million, with its median value being $44.8 million (2023).
  • Data for Adaptive Biotechnologies' Non-Current Deffered Revenue shows a maximum YoY tumbled of 40.66% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' Non-Current Deffered Revenue stood at $163.6 million in 2020, then crashed by 39.65% to $98.8 million in 2021, then plummeted by 40.66% to $58.6 million in 2022, then decreased by 23.56% to $44.8 million in 2023, then slumped by 39.15% to $27.3 million in 2024.